top of page
Loges, Sonja.jpg

Prof. Dr. Sonja Loges

Associated Member since 04/21 | Project

Department of Personalized Oncology

Medical Faculty Mannheim, Heidelberg University

 

​

 

Sonja.Loges(at)medma.uni-heidelberg.de

Sonja Loges is a Professor at the Medical Faculty Mannheim of Heidelberg University, Chair of the Department of Personalized Oncology at the University Hospital Mannheim as well as Head of the Division Personalized Medical Oncology at the German Cancer Research Center in Heidelberg. She obtained her PhD in Biochemistry and Molecular Biology at the University of Hamburg and her MD at the University Medical Center Hamburg, worked as postdoctoral researcher at VIB-KU Leuven, Belgium and finished her residency at the University Medical Center, Hamburg, where she also worked as Professor in the Department of Hematology and Oncology and group leader in the Department of Hematology and Oncology and Institute of Tumor Biology.

Qualifications and Scientific Curriculum

1998-2004

Medical School with Medical Examination, University Medical Center Hamburg​

​

PhD in Biochemistry and Molecular Biology, University of Hamburg, Department of Biology

​

Dr. med., University Medical Center Hamburg

​

Resident, Department of Hematology and Oncology, University Medical Center Hamburg

​

Post-Doctoral Researcher, VIB-KU Leuven, Belgium

​

Assistant Professor (Habilitation)

​

Resident, Department of Hematology and Oncology, University Medical Center Hamburg

​

Junior Group Leader, Department of Hematology and Oncology, Institute of Tumor Biology, University Medical Center Hamburg

​

Attending Physician and Group Leader, Department of Hematology and Oncology & Institute of Tumor Biology, University Medical Center Hamburg

​

Leader of Thoracic Oncology and Personalized Oncology Programs,         Department of Hematology and Oncology, University Medical Center             Hamburg

​

W3 Heisenberg Professor, Department of Hematology and Oncology,        University Medical Center Hamburg

​

Full W3 Professor, Medical Faculty Mannheim, University of Heidelberg and Chair of the Department of Personalized Oncology, University Hospital Mannheim

​

Head of Division Personalized Medical Oncology, DKFZ, Heidelberg

​

Scientific Director Mannheim Cancer Center, Mannheim

2000-2004

2005

2005-2007

2007-2010

2012

2010-2014

2010-2015

2015-2020

2015-2020

2016-2020

since 2020

since 2020

since 2021

Selected publications

​

  1. Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S: Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol. S0923-7534, 2022

  2. Carmeliet P, Li X, Treps L, Conradi LC, Loges S: RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients. Ann Oncol. 29:527-529, 2018.

  3. Bauer R*, Udonta F*, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner JM, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S: Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res. 78:3220-3232, 2018. (*equal contribution)

  4. Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S: Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. Nat Commun. 8:269, 2017.

  5. Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S: Role of growth arrest-specific gene 6-Mer axis in multiple myeloma. Leukemia. 29:696-704, 2015.

  6. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S: Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 122:2443-52, 2013.

  7. Schmidt T*, Kharabi Masouleh B*, Loges S*, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, De Keersmaecker K, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, De Mol M, Beel K, Dias S, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G, Dewerchin M, Carmeliet P.: Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell. 19:740-53, 2011. (*equal contribution)

  8. Loges S*, Schmidt T*, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Jonckx B, Carmeliet P: Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood. 115:2264-73, 2010. (*equal contribution)

  9. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I, Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic JM, Jiménez W, Noël A, Giacca M, Colle I, Foidart JM, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P: Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 141:178-90, 2010

  10. Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, Gehling M, Schuch G, Hossfeld DK, Fiedler W:. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol. 23:1109-17, 2005.

bottom of page